Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Structure Therapeutics (NASDAQ:GPCR), and Terns Pharmaceuticals (NASDAQ:TERN), which are all developing oral pills as weight loss treatments, are trading higher Friday following disappointing results ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Eli Lilly and Novo Nordisk the pharmaceutical heavyweights selling popular weight-loss injections are each dangling discounts to gain an edge and to ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Semaglutide injections effectively support weight loss by regulating appetite and glucose levels, offering benefits for ...

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Plus: The story behind the award-winning science that led to Ozempic, the next astronaut launch and why homework is good for ...